MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder
This review (2021) explores the potential of MDMA-assisted therapy for treating the various symptoms of social anxiety disorder (SAD). The authors hypothesize how disruptions in neurological, perceptual, receptive, and expressive systems regulating social behavior in SAD may take place as a result of MDMA-assisted therapy, thereby acting as a stimulus for further research.
Abstract
Social anxiety disorder (SAD) is a prevalent and often debilitating psychiatric disorder that can assume a chronic course even when treated. Despite the identification of evidence-based pharmacological and behavioral treatments for SAD, much room for improved outcomes exists and 3,4-methylenedioxymethamphetamine (MDMA) has been proposed as a promising adjunctive treatment to psychological interventions for disorders characterized by social dysfunction. A small randomized, placebo-controlled trial of MDMA-assisted therapy (MDMA-AT) for social anxiety in autistic adults offered encouraging results, but more research is sorely needed to explore the potential for MDMA-AT in treating SAD. This review aims to stimulate future study by summarizing research on disruptions in neurological, perceptual, receptive, and expressive systems regulating social behavior in SAD and proposing how MDMA-AT may alter these systems across four domains. First, we review research highlighting the roles of social anhedonia and reduced social reward sensitivity in maintaining SAD, with specific attention to the reduction in positive affect in social situations, infrequent social approach behaviors, and related social skills deficits. We posit that MDMA-AT may enhance motivation to connect with others and alter perceptions of social reward for an extended period following administration, thereby potentiating extinction processes, and increasing the reinforcement value of social interactions. Second, we review evidence for the central role of heightened social evaluative threat perception in the development and maintenance of SAD and consider how MDMA-AT may enhance experiences of affiliation and safety when interacting with others. Third, we consider the influence of shame and the rigid application of shame regulation strategies as important intrapersonal processes maintaining SAD and propose the generation of self-transcendent emotions during MDMA sessions as a mechanism of shame reduction that may result in corrective emotional experiences and boost memory reconsolidation. Finally, we review research on the role of dysfunctional interpersonal behaviors in SAD that interfere with social functioning and, in particular, the development and maintenance of close and secure relationships. We discuss the hypothesized role of MDMA-AT in improving social skills to elicit positive interpersonal responses from others, creating a greater sense of belonging, acceptance, and social efficacy.
Research Summary of 'MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder'
Introduction
Social anxiety disorder (SAD) is common and debilitating: the extracted text reports a lifetime prevalence of approximately 13% in the United States and a 12-month prevalence of about 8%. SAD is characterised by intense fear of social scrutiny, avoidance or marked distress in social situations, and broad negative downstream effects on relationships, education, employment and physical health. Evidence-based treatments exist—selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) and cognitive–behavioural therapy (CBT)—but substantial proportions of patients remain symptomatic after treatment, relapse occurs following medication discontinuation (the paper cites up to 25% relapse), and many people do not engage or respond fully to current options. Grob and colleagues set out to review how MDMA-assisted therapy (MDMA-AT) might alter the affective, cognitive, behavioural and neurological systems that maintain social dysfunction in SAD. Rather than focusing on acute subjective effects during dosing, the authors concentrate on downstream changes occurring weeks to months after administration. They organise the review around four interrelated domains hypothesised to be core to SAD maintenance and amenable to change with MDMA-AT: (1) social anhedonia and social reward sensitivity, (2) heightened social threat and social engagement system functioning, (3) shame and shame-related coping (notably self-criticism), and (4) dysfunctional interpersonal behaviours. The aim is to synthesise relevant basic and clinical evidence and to propose process-level pathways through which MDMA-AT could produce lasting therapeutic gains for SAD.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Author
- APA Citation
Luoma, J., & Lear, M. K. (2021). MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.733893
References (14)
Papers cited by this study that are also in Blossom
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Bahji, A., Forsyth, A., Groll, D. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020)
Heifets, B. D., Malenka, R. C. · Cell (2016)
Studerus, E., Gamma, A., Vollenweider, F. X. · PLOS ONE (2010)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Nardou, R., Lewis, E. M., Rothhaas, R. et al. · Nature (2019)
Curry, D. W., Berro, L. F., Belkoff, A. R. et al. · Neuropharmacology (2019)
Danforth, A. L., Grob, C. S., Struble, C. et al. · Psychopharmacology (2018)
Bershad, A. K., Miller, M. A., Baggot, M. J. et al. · Journal of Psychopharmacology (2016)
Show all 14 referencesShow fewer
Kamboj, S. K., Kilford, E. J., Minchin, S. et al. · Journal of Psychopharmacology (2015)
Kamboj, S. K., Walldén, Y. S. E., Falconer, C. J. et al. · Mindfulness (2017)
Barone, W., Beck, J., Mitsunaga-Whitten, M. et al. · Journal of Psychoactive Drugs (2019)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Cited By (3)
Papers in Blossom that reference this study
Luoma, J. B., Allen, L. R., Gold, V. et al. · Psychedelic Medicine (2024)
Jones, G. M., Lipson, J., Wang, E. · Scientific Reports (2023)
Hendricks, P. S., Simonsson, O. · Journal of Psychopharmacology (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.